{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T22:30:05Z","timestamp":1793399405821,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":5258,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1093\/annonc\/mdi235","type":"journal-article","created":{"date-parts":[[2005,5,31]],"date-time":"2005-05-31T22:49:19Z","timestamp":1117579759000},"page":"1223-1231","source":"Crossref","is-referenced-by-count":186,"title":["Myeloma bone disease: pathophysiology and management"],"prefix":"10.1016","volume":"16","author":[{"given":"E.","family":"Terpos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdi235_bb0010","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1365-2141.1996.d01-1491.x","article-title":"Serum interleukin-6 (IL-6) and interleukin-4 (IL-4) in patients with multiple myeloma (MM)","volume":"92","author":"Kyrtsonis","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0015","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1046\/j.1365-2141.1998.00835.x","article-title":"Chimaeric anti-interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose-escalating study","volume":"102","author":"van Zaanen","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0020","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood.V87.4.1495.bloodjournal8741495","article-title":"Development of an in vivo model of human multiple myeloma bone disease","volume":"87","author":"Alsina","year":"1996","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/sj.leu.2402374","article-title":"IL-1beta expression in IgM monoclonal gammopathy and its relationship to multiple myeloma","volume":"16","author":"Donovan","year":"2002","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdi235_bb0030","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1182\/blood-2003-06-1992","article-title":"IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells","volume":"103","author":"Lee","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0035","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1172\/JCI11176","article-title":"TNF-alpha induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand","volume":"106","author":"Lam","year":"2000","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdi235_bb0040","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2003-12-4386","article-title":"Multiple myeloma cells catalyze hepatocyte growth factor (HGF) activation by secreting the serine protease HGF-activator","volume":"104","author":"Tjin","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0045","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1046\/j.1365-2141.2002.03898.x","article-title":"Hepatocyte growth factor in myeloma patients treated with high-dose chemotherapy","volume":"119","author":"Seidel","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0050","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood.V95.8.2630","article-title":"Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma","volume":"95","author":"Dankbar","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0055","first-page":"174","article-title":"Osteopontin is an adhesive factor for myeloma cells and is found in increased levels in plasma from patients with multiple myeloma","volume":"89","author":"Standal","year":"2004","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdi235_bb0060","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1172\/JCI200113116","article-title":"Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease","volume":"108","author":"Choi","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1093\/annonc\/mdi235_bb0065","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","article-title":"Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma","volume":"100","author":"Abe","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0070","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1\u03b1) correlate with the extent of bone disease and survival in patients with Multiple Myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0075","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","article-title":"Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS)","volume":"126","author":"Politou","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1182\/blood-2002-12-3905","article-title":"Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease","volume":"102","author":"Oyajobi","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0085","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdi235_bb0090","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1093\/annonc\/mdi235_bb0095","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D","article-title":"Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases","volume":"92","author":"Hofbauer","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdi235_bb0100","first-page":"1118","article-title":"The RANK\/RANK ligand system is involved in intereleukin-6 and interleukin-11 up-regulation by human myeloma cells in the bone marrow microenvironment","volume":"89","author":"Giuliani","year":"2004","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdi235_bb0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1093\/annonc\/mdi235_bb0110","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1093\/annonc\/mdi235_bb0115","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","article-title":"Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment","volume":"98","author":"Giuliani","year":"2001","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0120","doi-asserted-by":"crossref","first-page":"4615","DOI":"10.1182\/blood-2002-04-1121","article-title":"Human myeloma cells stimulate the receptor activator of nuclear factor-\u03baB ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease","volume":"100","author":"Giuliani","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0125","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1034\/j.1600-065X.2003.00054.x","article-title":"Interpreting the molecular biology and clinical behavior of multiple myeloma in the context of global gene expression profiling","volume":"194","author":"Shaughnessy","year":"2003","journal-title":"Immunol Rev"},{"key":"10.1093\/annonc\/mdi235_bb0130","first-page":"1436","article-title":"Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma","volume":"9","author":"Heider","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdi235_bb0135","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1182\/blood-2002-04-1190","article-title":"Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells","volume":"100","author":"Standal","year":"2002","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0140","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor {kappa}B ligand (RANKL)\/osteoprotegerin (OPG) ratio predicts survival in multiple myeloma. Proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0145","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","article-title":"Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion","volume":"104","author":"Abe","year":"2004","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/j.1365-2141.2004.05084.x","article-title":"Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells","volume":"126","author":"Silvestris","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0155","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","article-title":"The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma","volume":"349","author":"Tian","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdi235_bb0160","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM200407083510223","article-title":"Bone lesions in molecular subtypes of multiple myeloma","volume":"351","author":"Robbiani","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdi235_bb0165","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1359\/jbmr.2003.18.3.482","article-title":"Zoledronic acid treatment of 5T2MM-bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and increased survival","volume":"18","author":"Croucher","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1093\/annonc\/mdi235_bb0170","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1365-2141.2002.03824.x","article-title":"Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma","volume":"119","author":"Gordon","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0175","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1200\/JCO.1991.9.8.1397","article-title":"Effect of daily etidronate on the osteolysis of multiple myeloma","volume":"9","author":"Belch","year":"1991","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi235_bb0180","first-page":"449","article-title":"Treatment of multiple myeloma with etidronate: results of a multicentre double-blind study","volume":"2","author":"Daragon","year":"1993","journal-title":"Eur J Med"},{"key":"10.1093\/annonc\/mdi235_bb0185","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/0140-6736(92)93075-X","article-title":"Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma","volume":"340","author":"Lahtinen","year":"1992","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdi235_bb0190","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/j.1365-2141.1994.tb06730.x","article-title":"Subgroup and cost-benefit analysis of the Finnish multicentre trial of clodronate in multiple myeloma","volume":"87","author":"Laakso","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0195","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2141.1998.00567.x","article-title":"A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukaemia in Adults","volume":"100","author":"McCloskey","year":"1998","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0200","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0205","first-page":"280","article-title":"Failure of oral pamidronate to reduce skeletal morbidity in multiple myeloma: a double-blind placebo-controlled trial","volume":"101","author":"Brincker","year":"1998","journal-title":"Danish-Swedish co-operative study group. Br J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0210","first-page":"488","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"Myeloma Aredia Study Group. N Engl J Med"},{"key":"10.1093\/annonc\/mdi235_bb0215","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi235_bb0220","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdi235_bb0225","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind","volume":"7","author":"Rosen","year":"2001","journal-title":"comparative trial. Cancer J"},{"key":"10.1093\/annonc\/mdi235_bb0230","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdi235_bb0235","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.2002.02.032","article-title":"Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma","volume":"20","author":"Menssen","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi235_bb0240","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003188","article-title":"Bisphosphonates in multiple myeloma","volume":"3","author":"Djulbegovic","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1093\/annonc\/mdi235_bb0245","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1034\/j.1600-0609.2003.02823.x","article-title":"Pamidronate is superior to ibandronate in decreasing bone resorption, interleukin-6 and beta 2-microglobulin in multiple myeloma","volume":"70","author":"Terpos","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0250","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi235_bb0255","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3109\/10428190309178778","article-title":"Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial","volume":"44","author":"Musto","year":"2003","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/annonc\/mdi235_bb0260","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/sj.thj.6200311","article-title":"Perspective study on pamidronate in stage I multiple myeloma","volume":"4","author":"Caparrotti","year":"2003","journal-title":"Hematol J"},{"key":"10.1093\/annonc\/mdi235_bb0265","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1034\/j.1600-0609.2000.065005331.x","article-title":"Effect of pamidronate administration on markers of bone turnover and disease activity in multiple myeloma","volume":"65","author":"Terpos","year":"2000","journal-title":"Eur J Haematol"},{"key":"10.1093\/annonc\/mdi235_bb0270","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/BF02390835","article-title":"Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment","volume":"68","author":"Terpos","year":"2001","journal-title":"Calcif Tissue Int"},{"key":"10.1093\/annonc\/mdi235_bb0275","first-page":"567","article-title":"Sequential analysis of biochemical markers of bone resorption and bone densitometry in multiple myeloma","volume":"89","author":"Abildgaard","year":"2004","journal-title":"Haematologica"},{"key":"10.1093\/annonc\/mdi235_bb0280","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/ijc.11247","article-title":"Tartrate-resistant acid phosphatase isoform 5b: a novel serum marker for monitoring bone disease in multiple myeloma","volume":"106","author":"Terpos","year":"2003","journal-title":"Int J Cancer"},{"key":"10.1093\/annonc\/mdi235_bb0285","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.leu.2403423","article-title":"Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL\/osteoprotegerin ratio in patients with multiple myeloma","volume":"18","author":"Terpos","year":"2004","journal-title":"Leukemia"},{"key":"10.1093\/annonc\/mdi235_bb0290","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood.V96.6.2037","article-title":"Solitary plasmacytoma of bone and asymptomatic multiple myeloma","volume":"96","author":"Dimopoulos","year":"2000","journal-title":"Blood"},{"key":"10.1093\/annonc\/mdi235_bb0295","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0936-6555(05)80091-3","article-title":"Double hemibody irradiation (DHBI) in the management of relapsed and primary chemoresistant multiple myeloma","volume":"5","author":"McSweeney","year":"1993","journal-title":"Clin Oncol"},{"key":"10.1093\/annonc\/mdi235_bb0300","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1259\/bjr\/10254271","article-title":"Percutaneous vertebroplasty: indications, contraindications, and technique","volume":"76","author":"Peh","year":"2003","journal-title":"Br J Radiol"},{"key":"10.1093\/annonc\/mdi235_bb0305","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1200\/JCO.2002.09.097","article-title":"Kyphoplasty in the treatment of osteolytic vertebral compression fractures as a result of multiple myeloma","volume":"20","author":"Dudeney","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdi235_bb0310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/000164701753759546","article-title":"Surgical treatment for pathologic fracture","volume":"72","author":"Wedin","year":"2001","journal-title":"Acta Orthop Scand Suppl"},{"key":"10.1093\/annonc\/mdi235_bb0315","doi-asserted-by":"crossref","first-page":"11581","DOI":"10.1073\/pnas.201394498","article-title":"Multiple myeloma disrupts the TRANCE\/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression","volume":"98","author":"Pearse","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1093\/annonc\/mdi235_bb0320","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res"},{"issue":"3 Suppl","key":"10.1093\/annonc\/mdi235_bb0325","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdi235_bb0330","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419549304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419549304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/16\/8\/1223\/317978\/mdi235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,23]],"date-time":"2021-06-23T03:43:09Z","timestamp":1624419789000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419549304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["S0923753419549304"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdi235","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}